Print

HVTN 114; GOVX-B11

A Phase 1 clinical trial to evaluate the immunogenicity of AIDSVAX? B/E bivalent gp120 vaccine and MVA/HIV62B in healthy, HIV-1 uninfected adult participants who previously received MVA/HIV62B in DNA/MVA or MVA/MVA regimens in HVTN 205

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) January 01, 2017
AIDSVAX B/E,MVA/HIV62 Protein Env B,E; Pox Gag, Evn, Pol B
AIDSVAX B/E Protein
MVA/HIV62 Viral Vector - Pox
USA 100
NCT02852005
https://www.clinicaltrials.gov/ct2/show/NCT02852005